Back

Potent and sustained blood pressure reduction with a novel small interfering RNA targeting hepatic angiotensinogen: results from a first-in-human, randomised, phase 1 study

29 August 2026 (14:50 - 15:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering in the prevention era: from statins to RNA therapeutics Angiotensin-Renin-Bradykinin System ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Mengchang Yang

Sichuan Provincial People's Hospital, Chengdu (China)

5 More presentations in this session

Presentation thumbnail
The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UK
Professor K. Ray (London, GB)
Abstract
Presentation thumbnail
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
Assistant Professor M. Leening (Rotterdam, NL)
Abstract
Presentation thumbnail
Real-world comparative outcomes of evolocumab versus high-intensity statin for primary prevention
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Reduction in total cardiovascular events with evolocumab in patients with no prior myocardial infarction or stroke: a pre-specified analysis of VESALIUS-CV
Professor J. Nicolau (Sao Paulo, BR)
Abstract
Presentation thumbnail
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials
Doctor S. Saluja (New Delhi, IN)
Abstract

Access the full session

Session thumbnail
Lipid lowering in the prevention era: from statins to RNA therapeutics

The Event

Event poster

ESC Congress 2026

29 August 2026 14:50 CET
You may be interested in
thumbnail
Congress Presentation
RNA interference for treating hypertension
31 August 2024
thumbnail
Congress Presentation
A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey
26 August 2022
thumbnail
Congress Presentation
Resistant hypertension improved after 3 months by measuring drug levels to identify non-adherence
27 August 2021
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources